Table 4.

Cross-correlations between periostin levels and other measured factors. Overall cross-correlation of the analysed parameters and cross-correlation performed in particular study subpopulations of particular interest (conventional therapy/omalizumab/patients without CRSwNP/patients with CRSwNP, Spearman’s rho)

			Age	Height	Weight	BMI	IgE [IU/ml]	ECP [μg/l]	AEC	eos %	FeNO [ppb]	FEV1 (l)	FEV1 (%pred)	OMA dose	Duration of OMA therapy	OMA cumulative dose
Periostin [ng/ml]	Whole sample N = 48	Spearman‘s rho	–0.178	–0.027	0.051	0.147	0.243	0.167	0.280	0.192	0.159	–0.117	–0.166
		Sig. (2-tailed)	0.227	0.853	0.732	0.317	0.096	0.290	0.054	0.192	0.285	0.438	0.259
	Conventional therapy N = 38	Spearman‘s rho	–0.235	–0.057	0.060	0.206	0.364	0.103	0.207	0.121	0.151	–0.129	–0.178
		Sig. (2-tailed)	0.155	0.732	0.720	0.215	0.025	0.575	0.214	0.468	0.373	0.446	0.286
	Omalizumab N = 10	Spearman‘s rho	–0.195	0.301	0.152	0.103	–0.115	0.455	0.382	0.515	0.522	–0.233	–0.055	–0.070	0.176	–0.036
		Sig. (2-tailed)	0.589	0.398	0.676	0.777	0.751	0.187	0.276	0.128	0.122	0.546	0.881	0.848	0.627	0.920
	Without CRSwNP N = 33	Spearman‘s rho	–0.194	0.148	0.086	0.034	0.270	0.175	0.401	0.396	0.308	–0.049	–0.202
		Sig. (2-tailed)	0.280	0.413	0.636	0.850	0.129	0.355	0.021	0.023	0.087	0.790	0.260
	With CRSwNP N = 15	Spearman‘s rho	–0.447	–0.667	–0.368	0.246	0.321	0.028	0.091	0.029	–0.349	–0.055	0.172
		Sig. (2-tailed)	0.095	0.007	0.177	0.376	0.243	0.931	0.747	0.919	0.203	0.852	0.541